Aspect Biosystems, a Canadian cell-therapy startup, secured $79 million from the Canadian government to support its diabetes programs. The funding is positioned as a way to keep next-generation diabetes manufacturing and development anchored in Canada. The investment highlights continued interest in cell-based approaches for diabetes beyond traditional insulin replacement, and it underlines how governments are increasingly willing to fund translational platforms that target long-term disease modification rather than short-acting symptom control.